Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 11:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: PsA (Psoriatic Arthritis) Clear all
Terminated Phase 2Phase 3 Interventional Results available

Psoriatic Arthritis Study of Izokibep

NCT05623345
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Izokibep, Placebo to izokibep
Drug
Lead sponsor
ACELYRIN Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
351 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
40
States / cities
Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated May 22, 2025 · Synced Jul 23, 2026, 11:17 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo

NCT02798211
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab 300 mg, Secukinumab 150 mg, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
57
States / cities
Birmingham, Alabama • Little Rock, Arkansas • El Cajon, California + 51 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Jul 23, 2026, 11:17 PM EDT
Completed Phase 3 Interventional Results available

Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis

NCT04209205
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
AIN457 6 mg/kg i.v., Placebo, AIN457 3 mg/kg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
31
States / cities
Birmingham, Alabama • Fountain Valley, California • Fullerton, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Jul 23, 2026, 11:17 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA)

NCT03881059
View directory record Official record
Conditions
Active Psoriatic Arthritis
Interventions
BMS-986165 Placebo, BMS-986165 Dose A, BMS-986165 Dose B, Ustekinumab, Ustekinumab Placebo
Other · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
31
States / cities
Huntsville, Alabama • Covina, California • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2022 · Synced Jul 23, 2026, 11:17 PM EDT
Completed No phase listed Observational

National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study

NCT01123265
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Methotrexate, Anti-TNF
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2015 · Synced Jul 23, 2026, 11:17 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

NCT03104400
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Adalimumab, Upadacitinib, Placebo to Upadacitinib, Placebo to Adalimumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
1,705 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
114
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 100 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jul 23, 2026, 11:17 PM EDT
Recruiting Phase 1 Interventional

A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)

NCT06888193
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis, Axial Spondyloarthritis, Hidradenitis Suppurativa
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Santa Monica, California • South Miami, Florida • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 23, 2026, 11:17 PM EDT
Terminated Phase 2 Interventional Results available

PsA Treatment With hOKT3γ1 (Ala-Ala)

NCT00239720
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
hOKT3gamma1(Ala-Ala), Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Aurora, Colorado • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Jul 23, 2026, 11:17 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis

NCT03347110
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
11
States / cities
Lexington, Kentucky • Hagerstown, Maryland • Lansing, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Jul 23, 2026, 11:17 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

NCT04806620
View directory record Official record
Conditions
Post-Acute COVID-19 Syndrome, ME/CFS, Rheumatic Arthritis, Juvenile Rheumatoid Arthritis (JRA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS), Autoimmune Encephalitis, Celiac Disease, Celiac Disease in Children, Chronic Lyme Disease, Post-treatment Lyme Disease Syndrome, Crohn's Disease, Dysautonomia, Anorexia Nervosa, Bulimia Nervosa, ARFID, Avoidant / Restrictive Food Intake Disorder, Ehlers Danlos Syndrome, Endometriosis, Fibromyalgia (FM), Long COVID, Lupus, Migraines, Mast Cell Activation Syndrome, Multiple Sclerosis, Myalgic Encephalomyelitis (ME), Myasthenia Gravis, Generalized, Myasthenia Gravis in Children, Narcolepsy, Obsessive Compulsive Disorder (OCD), PANDAS, Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), POTS - Postural Orthostatic Tachycardia Syndrome, General Anxiety Disorder, Social Anxiety Disorder, PTSD - Post Traumatic Stress Disorder, Psoriasis, Traumatic Brain Injury, Tourette's Syndrome, Inflammatory Bowel Disease (IBD), Autoimmune Diseases, Neurological Diseases or Conditions, Psychiatric Disorder, Sjogren's Syndrome, Ulcerative Colitis and Crohn's Disease
Interventions
Not listed
Lead sponsor
Brain Inflammation Collaborative
Other
Eligibility
2 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2030
U.S. locations
1
States / cities
Delafield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 23, 2026, 11:17 PM EDT
Completed Phase 4 Interventional

Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)

NCT03419650
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
ACTHar
Drug
Lead sponsor
IRIS Research and Development, LLC
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Jul 23, 2026, 11:17 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of SPY072 in Rheumatic Disease

NCT07148414
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases, Rheumatic Joint Disease, PsA (Psoriatic Arthritis), AxSpA, Rheumatologic Disease
Interventions
SPY002-072, Placebo
Drug
Lead sponsor
Spyre Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Avondale, Arizona • Tucson, Arizona • Chula Vista, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jul 23, 2026, 11:17 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis

NCT02969525
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Placebo, Bimekizumab
Other · Drug
Lead sponsor
UCB Biopharma S.P.R.L.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
13
States / cities
San Diego, California • Aventura, Florida • Hagerstown, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2023 · Synced Jul 23, 2026, 11:17 PM EDT
Not listed No phase listed Observational

Clinical and Molecular Characterization of Axial Psoriatic Arthritis (PsA), A Pilot Study

NCT05925842
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis
Network
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
La Jolla, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Jul 23, 2026, 11:17 PM EDT
Completed No phase listed Observational

DC-STAMP & TRAF3: Regulators of Osteoclastogenesis and Biomarkers in PsA

NCT02413749
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 89 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 17, 2017 · Synced Jul 23, 2026, 11:17 PM EDT
Recruiting Phase 4 Interventional

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

NCT06864026
View directory record Official record
Conditions
Psoriatic Arthritis, Overweight or Obesity
Interventions
Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
53
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jul 23, 2026, 11:17 PM EDT
Recruiting Phase 3 Interventional

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

NCT07286058
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Zasocitinib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
12
States / cities
Fountain Valley, California • Thousand Oaks, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 23, 2026, 11:17 PM EDT
Completed Phase 3 Interventional Results available

Efficacy at 24 Weeks With Long Term Safety, Tolerability and Efficacy up to 5 Years of Secukinumab in Patients of Active Psoriatic Arthritis

NCT01752634
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab (AIN457), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
21
States / cities
Peoria, Arizona • Aventura, Florida • Palm Harbor, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Jul 23, 2026, 11:17 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)

NCT02319759
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Guselkumab, Ustekinumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Huntsville, Alabama • Trumbull, Connecticut • Clearwater, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jul 23, 2026, 11:17 PM EDT
Completed Phase 3 Interventional

Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight

NCT06588296
View directory record Official record
Conditions
Psoriatic Arthritis, Obesity
Interventions
Ixekizumab, Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 80 Years
Enrollment
279 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
81
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 75 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jul 23, 2026, 11:17 PM EDT
Completed Phase 3 Interventional Results available

24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis

NCT01989468
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
12
States / cities
Aventura, Florida • Palm Harbor, Florida • Sarasota, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2019 · Synced Jul 23, 2026, 11:17 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis

NCT06869551
View directory record Official record
Conditions
Juvenile Psoriatic Arthritis
Interventions
Deucravacitinib, Placebo
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
5 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
7
States / cities
Lancaster, California • Chicago, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Jul 23, 2026, 11:17 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Adalimumab in Patients With Active Psoriatic Arthritis (PsA)

NCT00235885
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
adalimumab
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
445 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 28, 2007 · Synced Jul 23, 2026, 11:17 PM EDT
Completed Phase 3 Interventional Results available

Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)

NCT01392326
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Secukinumab (75 mg), Secukinumab (150 mg), Placebo Comparator
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
25
States / cities
Anniston, Alabama • Mesa, Arizona • Paradise Valley, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2016 · Synced Jul 23, 2026, 11:17 PM EDT